Aliases & Classifications for Cardiac Arrhythmia

MalaCards integrated aliases for Cardiac Arrhythmia:

Name: Cardiac Arrhythmia 57 29 6
Adverse Event Associated with Cardiac Arrhythmia 73
Premature Cardiac Complex 73
Extrasystoles 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
cardiac arrhythmia:
Mortality/Aging sudden death
Inheritance autosomal dominant inheritance


External Ids:

OMIM 57 115000
MedGen 42 C0003811
SNOMED-CT via HPO 69 263681008 88425004 26636000

Summaries for Cardiac Arrhythmia

MalaCards based summary : Cardiac Arrhythmia, also known as adverse event associated with cardiac arrhythmia, is related to cardiac conduction defect and long qt syndrome 13, and has symptoms including pulsus trigeminus and bigeminal pulse. An important gene associated with Cardiac Arrhythmia is TANGO2 (Transport And Golgi Organization 2 Homolog), and among its related pathways/superpathways are Circadian entrainment and Aldosterone synthesis and secretion. The drugs Methadone and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are abnormality of the nervous system and polymorphic and polytopic ventricular extrasystoles

Description from OMIM: 115000

Related Diseases for Cardiac Arrhythmia

Diseases related to Cardiac Arrhythmia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 235)
# Related Disease Score Top Affiliating Genes
1 cardiac conduction defect 31.9 KCNH2 KCNQ1 RYR2 SCN5A
2 long qt syndrome 13 31.6 SCN5A KCNQ1 KCNH2
3 arrhythmogenic right ventricular dysplasia, familial, 1 31.5 RYR2 JUP
4 arrhythmogenic right ventricular dysplasia, familial, 8 31.5 RYR2 JUP
5 long qt syndrome 9 31.5 SCN5A KCNJ2
6 long qt syndrome 12 30.9 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
7 brugada syndrome 1 30.8 SCN5A KCNH2
8 long qt syndrome 3 30.8 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1 ANK2
9 ventricular fibrillation, paroxysmal familial, 1 30.7 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 KCNE1
10 familial short qt syndrome 30.6 KCNQ1 KCNJ2 KCNH2
11 long qt syndrome 1 30.5 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
12 long qt syndrome 5 30.3 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
13 long qt syndrome 2 30.3 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
14 sick sinus syndrome 30.2 SCN5A RANGRF CACNA1C
15 left bundle branch hemiblock 30.2 SCN5A JUP
16 syncope 30.1 KCNH2 KCNJ2 KCNQ1 SCN5A
17 sudden infant death syndrome 30.1 SCN5A RYR2 KCNQ1 KCNH2
18 long qt syndrome 6 30.0 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
19 cardiac arrest 29.9 ANK2 KCNH2 KCNQ1 RYR2 SCN5A
20 brugada syndrome 29.9 SCN5A RANGRF KCNQ1 KCNH2 KCNE2 KCNE1
21 hypertrophic cardiomyopathy 29.7 SCN5A RYR2 CACNA1C
22 heart disease 29.6 CACNA1C KCNE2 KCNH2 KCNJ2 KCNQ1 RYR2
23 right bundle branch block 29.5 SCN5A CACNA1C
24 hypokalemic periodic paralysis, type 1 29.5 KCNJ2 CACNA1C
25 catecholaminergic polymorphic ventricular tachycardia 29.3 ANK2 KCNH2 KCNJ2 RYR2 SCN5A
26 arrhythmogenic right ventricular cardiomyopathy 29.3 SCN5A RYR2 KCNH2 JUP ANK2
27 atrioventricular block 29.3 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
28 atrial fibrillation 29.2 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
29 dilated cardiomyopathy 28.9 SCN5A RYR2 KCNQ1 KCNH2 JUP CACNA1C
30 long qt syndrome 28.9 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
31 jervell and lange-nielsen syndrome 1 28.7 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1 CACNA1C
32 intellectual developmental disorder with cardiac arrhythmia 12.6
33 language delay and attention deficit-hyperactivity disorder/cognitive impairment with or without cardiac arrhythmia 12.6
34 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 12.5
35 cardiac arrhythmia with increased serum creatine kinase 12.5
36 cardiac arrhythmia, ankyrin-b-related 12.4
37 extrasystoles, multiform ventricular, with short stature, hyperpigmentation and microcephaly 12.1
38 ventricular extrasystoles with syncope, perodactyly, and robin sequence 12.1
39 extrasystoles short stature hyperpigmentation microcephaly 12.0
40 ogden syndrome 11.7
41 tango2-related metabolic encephalopathy and arrhythmias 11.4
42 myotonic dystrophy 1 11.3
43 spondylometaphyseal dysplasia, sedaghatian type 11.3
44 hand and foot deformity with flat facies 11.1
45 carnitine palmitoyltransferase ii deficiency, lethal neonatal 11.1
46 thyrotoxic periodic paralysis 11.1
47 refsum disease, classic 11.0
48 heterotaxy, visceral, 1, x-linked 11.0
49 cardiomyopathy, infantile histiocytoid 11.0
50 hypomagnesemia 1, intestinal 11.0

Comorbidity relations with Cardiac Arrhythmia via Phenotypic Disease Network (PDN):


Chronic Myocardial Ischemia Familial Atrial Fibrillation
First-Degree Atrioventricular Block Heart Disease
Hypertension, Essential Intermediate Coronary Syndrome
Ischemic Heart Disease Mitral Valve Disease
Sinoatrial Node Disease

Graphical network of the top 20 diseases related to Cardiac Arrhythmia:



Diseases related to Cardiac Arrhythmia

Symptoms & Phenotypes for Cardiac Arrhythmia

Symptoms via clinical synopsis from OMIM:

57
Cardiac:
arrhythmia
polymorphic and polytopic ventricular extrasystoles

Neuro:
syncopal attacks

Misc:
sudden death


Clinical features from OMIM:

115000

Human phenotypes related to Cardiac Arrhythmia:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 32 HP:0000707
2 polymorphic and polytopic ventricular extrasystoles 32 HP:0006696

UMLS symptoms related to Cardiac Arrhythmia:


pulsus trigeminus, bigeminal pulse

MGI Mouse Phenotypes related to Cardiac Arrhythmia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.56 CACNA1C GNB5 JUP KCNH2 KCNJ2 KCNQ1
2 muscle MP:0005369 9.23 CACNA1C GNB5 JUP KCNH2 KCNJ2 KCNQ1

Drugs & Therapeutics for Cardiac Arrhythmia

Drugs for Cardiac Arrhythmia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 577)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methadone Approved Phase 4 76-99-3 4095
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
3
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
4
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
5
Racepinephrine Approved Phase 4,Phase 1,Not Applicable 329-65-7 838
6
Epinephrine Approved, Vet_approved Phase 4,Phase 1,Not Applicable 51-43-4 5816
7
Amiodarone Approved, Investigational Phase 4,Phase 3,Not Applicable 1951-25-3 2157
8
Apixaban Approved Phase 4,Phase 3 503612-47-3 10182969
9
Rivaroxaban Approved Phase 4,Phase 3 366789-02-8
10
Magnesium oxide Approved Phase 4,Not Applicable 1309-48-4 14792
11
Magnesium citrate Approved Phase 4,Not Applicable 3344-18-1
12
Milrinone Approved Phase 4,Phase 2,Not Applicable 78415-72-2 4197
13
Dobutamine Approved Phase 4,Phase 3,Not Applicable 34368-04-2 36811
14
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-61-7 60961
15 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
16
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
17
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
18
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 68602 5311068
19 fluindione Approved, Investigational Phase 4,Phase 3 957-56-2
20
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6
21
Bupivacaine Approved, Investigational Phase 4,Not Applicable 2180-92-9, 38396-39-3 2474
22
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 437-38-7 3345
23
Atropine Approved, Vet_approved Phase 4,Phase 2 51-55-8, 5908-99-6 174174
24
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
25
Procainamide Approved Phase 4,Phase 3,Not Applicable 51-06-9 4913
26
Ajmaline Approved, Experimental Phase 4 4360-12-7 441080
27
Oxytocin Approved, Vet_approved Phase 4,Early Phase 1,Not Applicable 50-56-6 439302 53477758
28
Carbetocin Approved, Investigational Phase 4,Not Applicable 37025-55-1 71715 16681432
29
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757
30
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 1 57-63-6 5991
31
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 1 28014-46-2
32 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 979-32-8
33
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 1 35189-28-7 6540478
34
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 354812-41-2, 151096-09-2 152946
35
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
36
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
37
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
38
Phytonadione Approved, Investigational Phase 4,Phase 3,Not Applicable 84-80-0 4812 5284607
39
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 6691 54678486
40
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
41
Morphine Approved, Investigational Phase 4 57-27-2 5288826
42
Ibutilide Approved Phase 4,Phase 2,Not Applicable 122647-32-9, 122647-31-8 60753
43
Metoprolol Approved, Investigational Phase 4,Not Applicable 37350-58-6, 51384-51-1 4171
44
Lypressin Approved Phase 4 50-57-7
45
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
46
Nivolumab Approved Phase 4 946414-94-4
47
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
48
Eplerenone Approved Phase 4,Phase 3 107724-20-9 443872 150310
49
Spironolactone Approved Phase 4,Phase 3,Phase 2 52-01-7, 1952-01-7 5833
50
Diltiazem Approved, Investigational Phase 4,Not Applicable 42399-41-7 39186

Interventional clinical trials:

(show top 50) (show all 902)
# Name Status NCT ID Phase Drugs
1 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
2 Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit Unknown status NCT02025855 Phase 4 Methadone;Placebo
3 Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery Unknown status NCT02672813 Phase 4
4 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV Unknown status NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
5 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
6 Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy Completed NCT00575523 Phase 4 Atropine;Placebo
7 Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias Completed NCT00702117 Phase 4 flecainide;ajmaline;procainamide
8 Ablation vs Amiodarone for Treatment of AFib in Patients With CHF and an ICD Active, not recruiting NCT00729911 Phase 4 Amiodarone
9 Carbetocin on Myocardial Repolarization Dynamics in Obstetrics Study Recruiting NCT03716076 Phase 4 Carbetocin
10 Reveal® XT Performance Trial (XPECT) Completed NCT00680927 Phase 4
11 Genetics of QT Response to Moxifloxacin Enrolling by invitation NCT01936480 Phase 4 Moxifloxacin 400mg once time;Placebo
12 Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics Completed NCT01719978 Phase 4 3.6mL 2% Mepivacaine with 1:100,000 epinephrine;Hyaluronidase;Placebo
13 Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145) Recruiting NCT03346057 Phase 4 Sugammadex 2 mg/kg;Sugammadex 4 mg/kg;Sugammadex 16 mg/kg;Neostigmine + Glycopyrrolate
14 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) Completed NCT02100228 Phase 4 Apixaban;Parenteral heparin and/or oral Vitamin K antagonist
15 Radiation Exposure Reduction in Supraventricular Tachycardia Ablation Completed NCT01132274 Phase 4
16 Atrial Fibrillation: Canadian Atrial Fibrillation Evaluation (CAFE) Study - Completed NCT00848445 Phase 4
17 ELIAS: Early Loop-Recorder in Suspected Arrhythmogenic Syncope Completed NCT00170261 Phase 4
18 Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management Completed NCT02335398 Phase 4 Methadone
19 Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery Completed NCT03800264 Phase 4 Bisoprolol
20 Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation Recruiting NCT02426944 Phase 4 NOAC
21 Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation Completed NCT01447862 Phase 4 Brinavess (Vernakalant);Corvert (Ibutilide)
22 Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter Completed NCT01448265 Phase 4
23 Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients Completed NCT01085071 Phase 4 Potassium Chloride;Potassium Chloride
24 Anticoagulation in AF Ablation and Effects on Neurocognitive Function Withdrawn NCT02120560 Phase 4
25 Open-Labeled PK-PD Studies of Metoprolol ER Active, not recruiting NCT02417246 Phase 4 Toprol XL;Wockhardt metoprolol;Activas metoprolol
26 Sleep Apnea-hypopnea Syndrome (SAHS) and Ventricular Arrhythmias Completed NCT00765713 Phase 4
27 Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation Completed NCT00247780 Phase 4
28 The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects Completed NCT00994006 Phase 4
29 Efficacy of Terlipressin Therapy in Acute Variceal Haemorrhage After EVL Recruiting NCT03584087 Phase 4 Normal Saline;Terlipressin
30 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 Not yet recruiting NCT03313544 Phase 4 Nivolumab
31 Assessment of the Effects of Atorvastatin Therapy on Myocardial Deformation Characteristics, in Patients With STEMI Recruiting NCT02590653 Phase 4 Atorvastatin
32 Atrial Fibrillation and Congestive Heart Failure Trial Completed NCT00597077 Phase 4
33 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit Completed NCT01461733 Phase 4 amiodarone;Placebo
34 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke Completed NCT00924638 Phase 4
35 Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation Completed NCT00552084 Phase 4 Fish oil;Placebo
36 A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart Completed NCT02415400 Phase 4 Apixaban;vitamin K antagonist;Acetylsalicylic acid
37 Hemodynamic Responses to Tracheal Intubation Direct Laryngoscope and Videolaryngoscope in Elderly Patients Completed NCT02816775 Phase 4
38 Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction Completed NCT01176968 Phase 4 Eplerenone;Placebo
39 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed NCT02090075 Phase 4 apixaban;warfarin
40 Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter Completed NCT01914926 Phase 4 Metoprolol;Diltiazem
41 Milrinone Versus Dobutamine in Critically Ill Patients Recruiting NCT03207165 Phase 4 Milrinone;Dobutamine
42 ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial Completed NCT01058980 Phase 4
43 (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes Not yet recruiting NCT03796195 Phase 4 .5% Bupivacaine
44 Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation Completed NCT03140631 Phase 4 Protamine Sulfate
45 The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation. Terminated NCT00232271 Phase 4 Clexane
46 Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol Terminated NCT01404767 Phase 4 Esmolol;Metoprolol
47 Study of Optimal Replacement of Thyroxine in the Elderly Completed NCT01647750 Phase 4 Levothyroxine;Levothyroxine
48 Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain Completed NCT03241602 Phase 4 Intraperitoneal lidocaine
49 Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol Completed NCT01174290 Phase 4 Haloperidol decanoate;Placebo
50 The Effect of Dexmedetomidine Infusion on Post-operative Cognitive Function and Oxidative Stress in Cardiac Surgery Completed NCT03054857 Phase 4 Dexmedetomidine;Placebo

Search NIH Clinical Center for Cardiac Arrhythmia

Genetic Tests for Cardiac Arrhythmia

Genetic tests related to Cardiac Arrhythmia:

# Genetic test Affiliating Genes
1 Cardiac Arrhythmia 29

Anatomical Context for Cardiac Arrhythmia

MalaCards organs/tissues related to Cardiac Arrhythmia:

41
Heart, Testes, Brain, Thyroid, Kidney, Lung, Endothelial

Publications for Cardiac Arrhythmia

Articles related to Cardiac Arrhythmia:

(show top 50) (show all 776)
# Title Authors Year
1
Special Program and Abstract issue of the 14th Annual Congress of the European Cardiac Arrhythmia Society (ECAS). ( 29546583 )
2018
2
Cardiac arrhythmia and neuroexcitability gene variants in resected brain tissue from patients with sudden unexpected death in epilepsy (SUDEP). ( 29619247 )
2018
3
Cardiac Arrhythmia Classification by Multi-Layer Perceptron and Convolution Neural Networks. ( 29734666 )
2018
4
Autonomic cardiovascular control and cardiac arrhythmia in two pregnant women with hypertrophic cardiomyopathy: Insights from ICD monitoring. ( 29678624 )
2018
5
Amiodarone for the Successful Management of Caowu Poisoning - Induced Cardiac Arrhythmia. ( 29643705 )
2018
6
Status of cardiac arrhythmia services in Africa in 2018: a PASCAR Sudden Cardiac Death Task Force report. ( 29745966 )
2018
7
Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and meta-analysis. ( 29740922 )
2018
8
Multiclass Classification of Cardiac Arrhythmia Using Improved Feature Selection and SVM Invariants. ( 29692863 )
2018
9
Is exposure to ionising radiation associated with childhood cardiac arrhythmia in the Russian territories contaminated by the Chernobyl fallout? A cross-sectional population-based study. ( 29581199 )
2018
10
Fatal cardiac arrhythmia caused by tumor lysis in a patient with diffuse large B-cell lymphoma upon start of R-CHOP. ( 29531724 )
2018
11
Effects of hawthorn ( Crataegus pentagyna) leaf extract on electrophysiologic properties of cardiomyocytes derived from human cardiac arrhythmia-specific induced pluripotent stem cells. ( 29133340 )
2018
12
European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). ( 29905786 )
2018
13
Kcne4 deletion sex-specifically predisposes to cardiac arrhythmia via testosterone-dependent impairment of RISK/SAFE pathway induction in aged mice. ( 29844497 )
2018
14
Retrospective multi-phase non-contrast-enhanced magnetic resonance angiography (ROMANCE MRA) for robust angiogram separation in the presence of cardiac arrhythmia. ( 29427402 )
2018
15
Design of a hybrid model for cardiac arrhythmia classification based on Daubechies wavelet transform. ( 29877638 )
2018
16
Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. ( 29961863 )
2018
17
Anxiety in children attending a specialist inherited cardiac arrhythmia clinic: a questionnaire study. ( 30234175 )
2018
18
Noninvasive cardiac arrhythmia ablation with particle beams. ( 30421810 )
2018
19
Real-Time Cardiac Arrhythmia Classification Using Memristor Neuromorphic Computing System. ( 30440932 )
2018
20
Statin use is associated with less postoperative cardiac arrhythmia after total hip arthroplasty. ( 30526117 )
2018
21
Conventional Acupuncture for Cardiac Arrhythmia: A Systematic Review of Randomized Controlled Trials. ( 28432528 )
2018
22
Intellectual developmental disorder with cardiac arrhythmia syndrome in a child with compound heterozygous GNB5 variants. ( 29368331 )
2018
23
Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patients. ( 29970732 )
2018
24
Transesophageal 2D ultrasound to 3D computed tomography registration for the guidance of a cardiac arrhythmia therapy. ( 29992909 )
2018
25
The effect of ambient particle matters on hospital admissions for cardiac arrhythmia: a multi-city case-crossover study in China. ( 30012150 )
2018
26
Effects of Pinocembrin Pretreatment on Connexin 43 (Cx43) Protein Expression After Rat Myocardial Ischemia-Reperfusion and Cardiac Arrhythmia. ( 30022020 )
2018
27
Mutations in voltage-gated L-type calcium channel: implications in cardiac arrhythmia. ( 30027834 )
2018
28
2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). ( 30052888 )
2018
29
Opioids and Cardiac Arrhythmia: A Literature Review. ( 30071529 )
2018
30
A Heart for Diversity: Simulating Variability in Cardiac Arrhythmia Research. ( 30079031 )
2018
31
Management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCI: A Summary of the Joint Consensus Document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). ( 30137444 )
2018
32
Can Intradetrusor OnabotulinumtoxinA Injections Alter Heart Function in Patients with Cardiac Arrhythmia? ( 30205603 )
2018
33
Aconitine-induced cardiac arrhythmia in human induced pluripotent stem cell-derived cardiomyocytes. ( 30233701 )
2018
34
A Case of Cardiac Arrhythmia from Absorption of Normal Saline during Hysteroscopic Myomectomy. ( 30267897 )
2018
35
Machine-Learning Prediction of Drug-Induced Cardiac Arrhythmia: Analysis of Gene Expression and Clustering. ( 30311557 )
2018
36
A Novel Familial Cardiac Arrhythmia Syndrome with Widespread ST-Segment Depression. ( 30380381 )
2018
37
Wrapper method for feature selection to classify cardiac arrhythmia. ( 29060691 )
2017
38
Detection and characterization of intermittent complexity variations in cardiac arrhythmia. ( 28746052 )
2017
39
Impact of Supraventricular Tachyarrhythmia in Patients With Inherited Cardiac Arrhythmia. ( 28951021 )
2017
40
Current state of the art for cardiac arrhythmia gene therapy. ( 28642118 )
2017
41
Phosphorylation of serine96 of histidine-rich calcium-binding protein by the Fam20C kinase functions to prevent cardiac arrhythmia. ( 28784772 )
2017
42
Promoting cardiac arrhythmia care in Africa: a big challenge that begins with data. ( 29309583 )
2017
43
Allele-Specific Gene Silencing: Another Step in the Inexorable Advance of Gene Therapy for Cardiac Arrhythmia Management. ( 28819033 )
2017
44
Inhaled nicotine equivalent to cigarette smoking disrupts systemic and uterine hemodynamics and induces cardiac arrhythmia in pregnant rats. ( 29209071 )
2017
45
Cardiac arrhythmia detection using photoplethysmography. ( 29059823 )
2017
46
Sleep Apnea and Nocturnal Cardiac Arrhythmia: Understanding Differences Across Ethnicity. ( 29065964 )
2017
47
Applications of Dynamic Clamp to Cardiac Arrhythmia Research: Role in Drug Target Discovery and Safety Pharmacology Testing. ( 29354069 )
2017
48
ECG-based 4D-dose reconstruction of cardiac arrhythmia ablation with carbon ion beams: application in a porcine model. ( 28644151 )
2017
49
Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de EstimulaciA^n CardA-aca y ElectrofisiologA-a (SOLEACE). ( 29212110 )
2017
50
Numerous Brugada syndrome-associated genetic variants have no effect on J-point elevation, syncope susceptibility, malignant cardiac arrhythmia, and all-cause mortality. ( 27711072 )
2017

Variations for Cardiac Arrhythmia

ClinVar genetic disease variations for Cardiac Arrhythmia:

6 (show top 50) (show all 209)
# Gene Variation Type Significance SNP ID Assembly Location
1 KCNE2 NM_172201.1(KCNE2): c.161T> C (p.Met54Thr) single nucleotide variant risk factor rs74315447 GRCh37 Chromosome 21, 35742938: 35742938
2 KCNE2 NM_172201.1(KCNE2): c.161T> C (p.Met54Thr) single nucleotide variant risk factor rs74315447 GRCh38 Chromosome 21, 34370639: 34370639
3 KCNE2 NM_172201.1(KCNE2): c.170T> C (p.Ile57Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs74315448 GRCh37 Chromosome 21, 35742947: 35742947
4 KCNE2 NM_172201.1(KCNE2): c.170T> C (p.Ile57Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs74315448 GRCh38 Chromosome 21, 34370648: 34370648
5 SCN5A NM_198056.2(SCN5A): c.3308C> A (p.Ser1103Tyr) single nucleotide variant risk factor rs7626962 GRCh37 Chromosome 3, 38620907: 38620907
6 SCN5A NM_198056.2(SCN5A): c.3308C> A (p.Ser1103Tyr) single nucleotide variant risk factor rs7626962 GRCh38 Chromosome 3, 38579416: 38579416
7 ANK2 NM_001148.4(ANK2): c.11231C> A (p.Thr3744Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs121912705 GRCh37 Chromosome 4, 114288920: 114288920
8 ANK2 NM_001148.4(ANK2): c.11231C> A (p.Thr3744Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs121912705 GRCh38 Chromosome 4, 113367764: 113367764
9 ANK2 NM_001148.4(ANK2): c.11218C> A (p.Leu3740Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs35530544 GRCh37 Chromosome 4, 114288907: 114288907
10 ANK2 NM_001148.4(ANK2): c.11218C> A (p.Leu3740Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs35530544 GRCh38 Chromosome 4, 113367751: 113367751
11 ANK2 NM_001148.4(ANK2): c.11716C> T (p.Arg3906Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs121912706 GRCh37 Chromosome 4, 114294462: 114294462
12 ANK2 NM_001148.4(ANK2): c.11716C> T (p.Arg3906Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs121912706 GRCh38 Chromosome 4, 113373306: 113373306
13 ANK2 NM_001148.4(ANK2): c.11791G> A (p.Glu3931Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs45454496 GRCh37 Chromosome 4, 114294537: 114294537
14 ANK2 NM_001148.4(ANK2): c.11791G> A (p.Glu3931Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs45454496 GRCh38 Chromosome 4, 113373381: 113373381
15 NPPA NM_006172.3(NPPA): c.123+16C> T single nucleotide variant Benign rs5064 GRCh38 Chromosome 1, 11847546: 11847546
16 AKAP9 NM_147185.2(AKAP9): c.4837A> G (p.Met1613Val) single nucleotide variant Conflicting interpretations of pathogenicity rs193922723 GRCh37 Chromosome 7, 91670132: 91670132
17 AKAP9 NM_147185.2(AKAP9): c.4837A> G (p.Met1613Val) single nucleotide variant Conflicting interpretations of pathogenicity rs193922723 GRCh38 Chromosome 7, 92040818: 92040818
18 ANK2 NM_001127493.1(ANK2): c.3483A> G (p.Val1161=) single nucleotide variant Benign/Likely benign rs35336373 GRCh37 Chromosome 4, 114257132: 114257132
19 ANK2 NM_001127493.1(ANK2): c.3483A> G (p.Val1161=) single nucleotide variant Benign/Likely benign rs35336373 GRCh38 Chromosome 4, 113335976: 113335976
20 ANK2 NM_001127493.1(ANK2): c.3769+18G> A single nucleotide variant Uncertain significance rs66792339 GRCh37 Chromosome 4, 114257955: 114257955
21 ANK2 NM_001127493.1(ANK2): c.3769+18G> A single nucleotide variant Uncertain significance rs66792339 GRCh38 Chromosome 4, 113336799: 113336799
22 ANK2 NM_001127493.1(ANK2): c.321+19C> T single nucleotide variant Benign rs45502093 GRCh37 Chromosome 4, 114120284: 114120284
23 ANK2 NM_001127493.1(ANK2): c.321+19C> T single nucleotide variant Benign rs45502093 GRCh38 Chromosome 4, 113199128: 113199128
24 ANK2 NM_001148.4(ANK2): c.7106T> C (p.Val2369Ala) single nucleotide variant Benign/Likely benign rs28377576 GRCh37 Chromosome 4, 114276880: 114276880
25 ANK2 NM_001148.4(ANK2): c.7106T> C (p.Val2369Ala) single nucleotide variant Benign/Likely benign rs28377576 GRCh38 Chromosome 4, 113355724: 113355724
26 ANK2 NM_001127493.1(ANK2): c.4400-4039G> A single nucleotide variant Conflicting interpretations of pathogenicity rs193922637 GRCh37 Chromosome 4, 114277940: 114277940
27 ANK2 NM_001127493.1(ANK2): c.4400-4039G> A single nucleotide variant Conflicting interpretations of pathogenicity rs193922637 GRCh38 Chromosome 4, 113356784: 113356784
28 ATP1B1; NME7 NM_001677.3(ATP1B1): c.571C> T (p.Pro191Ser) single nucleotide variant Uncertain significance rs267598155 GRCh37 Chromosome 1, 169099251: 169099251
29 ATP1B1; NME7 NM_001677.3(ATP1B1): c.571C> T (p.Pro191Ser) single nucleotide variant Uncertain significance rs267598155 GRCh38 Chromosome 1, 169130013: 169130013
30 ATP1B1; NME7 NM_001677.3(ATP1B1): c.571C> T (p.Pro191Ser) single nucleotide variant Uncertain significance rs267598155 NCBI36 Chromosome 1, 167365875: 167365875
31 CACNA1C NM_000719.6(CACNA1C): c.171C> T (p.Asp57=) single nucleotide variant Benign/Likely benign rs34419050 GRCh37 Chromosome 12, 2224511: 2224511
32 CACNA1C NM_000719.6(CACNA1C): c.171C> T (p.Asp57=) single nucleotide variant Benign/Likely benign rs34419050 GRCh38 Chromosome 12, 2115345: 2115345
33 CACNA1C NM_000719.6(CACNA1C): c.372-15G> A single nucleotide variant Benign/Likely benign rs55792866 GRCh37 Chromosome 12, 2229476: 2229476
34 CACNA1C NM_000719.6(CACNA1C): c.372-15G> A single nucleotide variant Benign/Likely benign rs55792866 GRCh38 Chromosome 12, 2120310: 2120310
35 CACNA1C NM_000719.6(CACNA1C): c.5680+15C> T single nucleotide variant Benign/Likely benign rs114036394 GRCh37 Chromosome 12, 2795023: 2795023
36 CACNA1C NM_000719.6(CACNA1C): c.5680+15C> T single nucleotide variant Benign/Likely benign rs114036394 GRCh38 Chromosome 12, 2685857: 2685857
37 CACNA1C NM_000719.6(CACNA1C): c.6031G> A (p.Val2011Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs193922615 GRCh37 Chromosome 12, 2797859: 2797859
38 CACNA1C NM_000719.6(CACNA1C): c.6031G> A (p.Val2011Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs193922615 GRCh38 Chromosome 12, 2688693: 2688693
39 CACNA1C NM_000719.6(CACNA1C): c.6307G> T (p.Ala2103Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs193922616 GRCh37 Chromosome 12, 2800255: 2800255
40 CACNA1C NM_000719.6(CACNA1C): c.6307G> T (p.Ala2103Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs193922616 GRCh38 Chromosome 12, 2691089: 2691089
41 CASQ2 NM_001232.3(CASQ2): c.731A> G (p.His244Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs28730716 GRCh37 Chromosome 1, 116269619: 116269619
42 CASQ2 NM_001232.3(CASQ2): c.731A> G (p.His244Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs28730716 GRCh38 Chromosome 1, 115726998: 115726998
43 DSG2 NM_001943.4(DSG2): c.3135A> C (p.Thr1045=) single nucleotide variant Benign rs8095704 GRCh37 Chromosome 18, 29126484: 29126484
44 DSG2 NM_001943.4(DSG2): c.3135A> C (p.Thr1045=) single nucleotide variant Benign rs8095704 GRCh38 Chromosome 18, 31546521: 31546521
45 JUP NM_002230.2(JUP): c.1774-13C> T single nucleotide variant Benign/Likely benign rs116772523 GRCh37 Chromosome 17, 39914049: 39914049
46 JUP NM_002230.2(JUP): c.1774-13C> T single nucleotide variant Benign/Likely benign rs116772523 GRCh38 Chromosome 17, 41757797: 41757797
47 JUP NM_002230.2(JUP): c.867C> T (p.Thr289=) single nucleotide variant Benign/Likely benign rs2230407 GRCh37 Chromosome 17, 39923673: 39923673
48 JUP NM_002230.2(JUP): c.867C> T (p.Thr289=) single nucleotide variant Benign/Likely benign rs2230407 GRCh38 Chromosome 17, 41767421: 41767421
49 JUP NM_002230.2(JUP): c.909+6C> T single nucleotide variant Conflicting interpretations of pathogenicity rs193922705 GRCh37 Chromosome 17, 39923625: 39923625
50 JUP NM_002230.2(JUP): c.909+6C> T single nucleotide variant Conflicting interpretations of pathogenicity rs193922705 GRCh38 Chromosome 17, 41767373: 41767373

Expression for Cardiac Arrhythmia

Search GEO for disease gene expression data for Cardiac Arrhythmia.

Pathways for Cardiac Arrhythmia

Pathways related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 CACNA1C GNB5 KCNJ2 KCNQ1 RYR2
2
Show member pathways
12.48 CACNA1C KCNE1 KCNQ1 RYR2 SCN5A
3
Show member pathways
12.34 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
4 12.16 CACNA1C GNB5 KCNE1 KCNE2 KCNH2 KCNJ2
5 11.88 KCNH2 KCNQ1 RYR2 SCN5A
6
Show member pathways
11.87 KCNE2 KCNJ2 KCNQ1
7
Show member pathways
11.8 KCNH2 KCNJ2 KCNQ1
8
Show member pathways
11.51 CACNA1C KCNE1 KCNE2 KCNQ1 RANGRF SCN5A
9 11.07 ANK2 CACNA1C JUP KCNE1 KCNE2 KCNH2
10 10.97 ANK2 SCN5A
11 10.78 KCNE1 KCNJ2 KCNQ1

GO Terms for Cardiac Arrhythmia

Cellular components related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysosome GO:0005764 9.73 ANK2 KCNE1 KCNE2 KCNQ1
2 membrane raft GO:0045121 9.65 ANK2 KCNE1 KCNQ1
3 sarcolemma GO:0042383 9.62 ANK2 CACNA1C RYR2 SCN5A
4 voltage-gated potassium channel complex GO:0008076 9.55 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
5 T-tubule GO:0030315 9.54 ANK2 KCNJ2 SCN5A
6 smooth endoplasmic reticulum GO:0005790 9.46 KCNJ2 RYR2
7 intercalated disc GO:0014704 9.35 ANK2 JUP KCNJ2 RANGRF SCN5A
8 Z disc GO:0030018 9.1 ANK2 CACNA1C JUP KCNE1 RYR2 SCN5A
9 membrane GO:0016020 10.18 ANK2 CACNA1C GNB5 JUP KCNE1 KCNE2
10 plasma membrane GO:0005886 10.03 ANK2 CACNA1C GNB5 JUP KCNE1 KCNE2

Biological processes related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.98 CACNA1C KCNQ1 RYR2 SCN5A
2 potassium ion transport GO:0006813 9.97 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
3 potassium ion transmembrane transport GO:0071805 9.96 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
4 regulation of ion transmembrane transport GO:0034765 9.91 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
5 cardiac muscle contraction GO:0060048 9.88 KCNH2 KCNQ1 RYR2 SCN5A
6 regulation of heart rate GO:0002027 9.85 ANK2 RANGRF RYR2 SCN5A
7 cellular response to drug GO:0035690 9.83 KCNE2 KCNH2 KCNQ1
8 positive regulation of potassium ion transmembrane transport GO:1901381 9.83 KCNE1 KCNH2 KCNJ2 KCNQ1
9 potassium ion export across plasma membrane GO:0097623 9.81 KCNE1 KCNE2 KCNH2 KCNQ1
10 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.8 KCNE1 KCNE2 KCNH2 KCNQ1
11 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.79 ANK2 CACNA1C RYR2
12 regulation of potassium ion transmembrane transport GO:1901379 9.79 KCNE1 KCNE2 KCNH2
13 regulation of cardiac muscle cell contraction GO:0086004 9.78 ANK2 KCNJ2 SCN5A
14 potassium ion export GO:0071435 9.78 KCNE1 KCNE2 KCNH2 KCNQ1
15 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.77 CACNA1C KCNJ2 SCN5A
16 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.77 CACNA1C JUP RYR2
17 atrial cardiac muscle cell action potential GO:0086014 9.76 ANK2 KCNQ1 SCN5A
18 regulation of membrane repolarization GO:0060306 9.76 KCNE2 KCNH2 KCNJ2 KCNQ1
19 membrane repolarization GO:0086009 9.73 KCNE1 KCNE2 KCNH2 KCNQ1
20 cardiac muscle cell action potential involved in contraction GO:0086002 9.72 CACNA1C KCNE1 KCNE2 KCNJ2 SCN5A
21 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.71 KCNE1 KCNH2 KCNJ2 KCNQ1
22 potassium ion import across plasma membrane GO:1990573 9.7 KCNE2 KCNJ2
23 potassium ion import GO:0010107 9.7 KCNE2 KCNJ2
24 positive regulation of heart rate GO:0010460 9.7 KCNQ1 RYR2
25 regulation of cardiac muscle contraction GO:0055117 9.69 ANK2 RYR2
26 membrane depolarization during action potential GO:0086010 9.69 KCNH2 SCN5A
27 negative regulation of delayed rectifier potassium channel activity GO:1902260 9.69 KCNE1 KCNE2
28 calcium ion transport into cytosol GO:0060402 9.68 CACNA1C RYR2
29 cell communication by electrical coupling involved in cardiac conduction GO:0086064 9.68 CACNA1C RYR2
30 cellular response to epinephrine stimulus GO:0071872 9.68 KCNQ1 RYR2
31 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.67 ANK2 RYR2
32 regulation of sodium ion transmembrane transport GO:1902305 9.67 RANGRF SCN5A
33 regulation of delayed rectifier potassium channel activity GO:1902259 9.66 KCNE1 KCNE2
34 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.65 KCNQ1 SCN5A
35 SA node cell action potential GO:0086015 9.65 ANK2 SCN5A
36 membrane depolarization during AV node cell action potential GO:0086045 9.65 CACNA1C SCN5A
37 membrane repolarization during action potential GO:0086011 9.65 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
38 membrane depolarization during SA node cell action potential GO:0086046 9.64 ANK2 SCN5A
39 sarcoplasmic reticulum calcium ion transport GO:0070296 9.64 ANK2 RYR2
40 membrane depolarization during atrial cardiac muscle cell action potential GO:0098912 9.63 CACNA1C SCN5A
41 regulation of atrial cardiac muscle cell action potential GO:0098910 9.63 ANK2 RYR2
42 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.63 ANK2 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
43 regulation of SA node cell action potential GO:0098907 9.62 ANK2 RYR2
44 regulation of heart rate by cardiac conduction GO:0086091 9.61 ANK2 CACNA1C JUP KCNE1 KCNE2 KCNH2
45 ventricular cardiac muscle cell action potential GO:0086005 9.17 ANK2 KCNE1 KCNE2 KCNH2 KCNQ1 RYR2
46 ion transport GO:0006811 10.14 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
47 transmembrane transport GO:0055085 10.06 CACNA1C KCNH2 KCNQ1 RYR2 SCN5A

Molecular functions related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.84 ANK2 JUP RYR2 SCN5A
2 calmodulin binding GO:0005516 9.78 CACNA1C KCNQ1 RYR2 SCN5A
3 ion channel activity GO:0005216 9.76 CACNA1C KCNH2 RYR2 SCN5A
4 potassium channel activity GO:0005267 9.71 KCNE1 KCNE2 KCNH2 KCNQ1
5 scaffold protein binding GO:0097110 9.67 KCNH2 KCNQ1 SCN5A
6 voltage-gated potassium channel activity GO:0005249 9.67 KCNE1 KCNE2 KCNH2 KCNQ1
7 voltage-gated ion channel activity GO:0005244 9.63 CACNA1C KCNE2 KCNH2 KCNJ2 KCNQ1 SCN5A
8 delayed rectifier potassium channel activity GO:0005251 9.62 KCNE1 KCNE2 KCNH2 KCNQ1
9 inward rectifier potassium channel activity GO:0005242 9.61 KCNE2 KCNH2 KCNJ2
10 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.56 KCNE1 KCNE2 KCNH2 KCNQ1
11 potassium channel regulator activity GO:0015459 9.55 KCNE1 KCNE2
12 protein kinase A regulatory subunit binding GO:0034237 9.52 KCNQ1 RYR2
13 protein kinase A catalytic subunit binding GO:0034236 9.51 KCNQ1 RYR2
14 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 9.26 KCNE1 KCNH2 KCNJ2 KCNQ1
15 ion channel binding GO:0044325 9.17 ANK2 KCNE1 KCNE2 KCNQ1 RANGRF RYR2

Sources for Cardiac Arrhythmia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....